Navigation Links
Cepheid Reports 2012 First Quarter Results
Date:4/19/2012

 Three Months Ended March 31,20122011ChangeClinical Systems

$
2.5$
.68%Clinical Reagents

54.438.641%Total Clinical 66.950.233%Non-Clinical

8.47.413%Total Product Sales$
75.3$
57.631%--

By geography, product sales were, in millions: Three Months Ended March 31,20122011ChangeNorth AmericaClinical

$
45.5$
36.325%Non-Clinical

6.95.916%Total North America52.442.224%InternationalClinical

21.413.954%Non-Clinical

1.51.52%Total International22.915.449%Total Product Sales$
75.3$
57.631% 

--

During the quarter, Cepheid installed a total of 122 GeneXpert systems in its commercial Clinical business.  Additionally,
the Company placed a total of 151 GeneXpert systems as part of its High Burden Developing Country (HBDC) program.
Including the HBDC systems, a cumulative total of 3,079 GeneXpert systems have been placed worldwide as of March 31, 2012.

 --

GAAP gross margin on product sales was 53% and non-GAAP gross margin on product sales was 54%, which compares to
56% and 58%, respectively, in the first quarter of 2011.  Gross margin was impacted by higher than expected costs associated
with freight and with the scale-up of our manufacturing operations, in addition to higher Group Purchasing Organization (GPO)
fees recorded as contra revenue. 

 --

GAAP research and development (R&D) expense was 29% of total revenue and non-GAAP research and development expense
was 26% of total revenue, which compares to 23% and 20%, respectively, in the first quarter of 2011.  R&D expense included
higher than expected costs associated with the early completion of our CT/NG trial, including an increase in patient enrollment.

 --

Cash and cash equivalents were $104.0 million as of March 31, 2012.

 --

DSO was 42 days.Busine
'/>"/>

SOURCE Cepheid
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Cepheid Schedules 2011 Third Quarter Financial Results Announcement and Webcast
2. Cepheid Announces Release of Updated Xpert BCR-ABL Monitor Test
3. Cepheid to Webcast Upcoming Financial Presentations
4. Cepheid Schedules 2011 Second Quarter Financial Results Announcement and Webcast
5. Cepheid CEO John Bishop Named Ernst & Young Entrepreneur Of The Year® 2011 Northern California Award winner
6. Cepheid Appoints Vice President of Infectious Disease Research & Development
7. LABSCO to Distribute Cepheid GeneXpert® Systems and Tests
8. Cepheid Appoints LABSCO as US Small Hospital Distributor
9. Cepheid Reports 2011 First Quarter Results
10. Cepheid Extends Rapid Molecular Diagnostics Leadership with FDA Clearance of Xpert Clostridium difficile/Epi
11. Cepheid Announces Nomination of Geisinger Health System CEO and Renowned Oncology Researcher to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... 2014 UBM Medica US announces that ... and information resource for neurologists and other healthcare providers, features ... disease , with discussions of the latest developments in approaches ... have Parkinson disease , more than the total of those ... disease. Diagnosis can be difficult because there are no ...
(Date:10/17/2014)... DALLAS , October 17, 2014 /PRNewswire/ ... research report "Optical Imaging Market by Technique (Optical ... System, Imaging software) & by Application (Ophthalmology, Neurology, Oncology, ... by MarketsandMarkets, this report studies the Optical Imaging ... The market was valued at $917.1 million ...
(Date:10/17/2014)... -- Investor-Edge has initiated coverage on the ... ), NPS Pharmaceuticals Inc. (NASDAQ: NPSP ), ... Inc. (NASDAQ: MNTA ), and Catalyst Pharmaceutical ... companies can be accessed at: http://investor-edge.com/register . ... ended on a mixed note as the Dow Jones ...
Breaking Medicine Technology:Neurology Times Features Coverage of Parkinson and Alzheimer Disease 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 3Optical Imaging Market Worth $1,669.2 Million by 2019 2Optical Imaging Market Worth $1,669.2 Million by 2019 3Optical Imaging Market Worth $1,669.2 Million by 2019 4Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 2Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 4Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 5
... PHILADELPHIA, Sept. 9 Compliance Implementation Services (CIS), ... it has been named to Inc. Magazine,s fourth ... companies in the United States. (Logo: ... ) "The leaders of the companies ...
... have an increased risk of developing venous thromboembolism (VTE) due to ... model to predict their chance of developing blood clots, according to ... the journal of the American Society of Hematology. VTE, the formation ... percent of cancer patients and is one of the leading causes ...
Cached Medicine Technology:Despite Economic Turmoil, CIS Named to Inc. 5000 List of Fastest-Growing Private Companies in America 2Improvement in Prediction of Blood Clots in Cancer Patients 2Improvement in Prediction of Blood Clots in Cancer Patients 3
(Date:10/20/2014)... 2014 JZ Fitness, an independently operated ... wellness programming, authorship, international lecturing and community wellness, created ... the release of the JZ Fitness nutrition app, available ... coaching thousands of individuals on nutrition, Jenn Zerling (“JZ”) ... not require calorie counting or cumbersome food logging. ...
(Date:10/20/2014)... 20, 2014 AttorneyOne.com, a recognized authority on ... from the FDA on Sit and Slim II . ... to purchase or use Sit and Slim II because it ... is promoted as weight loss product on various websites and ... market in 2010 for safety reasons, can significantly increase blood ...
(Date:10/20/2014)... Succeed is proud to announce that they ranked ... the Every Body Walk! campaign by Kaiser Permanente. ... encourages workers to be more active outside of the workplace. ... at the end of September, was a friendly competition between ... Participating companies gave their staff pedometers and each day, ...
(Date:10/20/2014)... 2014 Final Cut Pro X Plugin developers ... Citrus theme for FCPX filmmakers . , “Fun, cool, ... the Citrus theme” Says Christina Austin, CEO of Pixel Film ... professional.” , Citrus comes with all the tools needed for ... four transitions for added style, a title screen for an ...
(Date:10/20/2014)... Punzoné , the first line of ... a lot to celebrate this month. October marks Italian Heritage ... and contributions of Americans of Italian heritage and Italians in ... it shares its favorite Italian cocktails and encourages everyone to ... even if it is only in a glass. , ...
Breaking Medicine News(10 mins):Health News:JZ Fitness Nutrition App Launches on iTunes 2Health News:JZ Fitness Nutrition App Launches on iTunes 3Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 4
... worldwide as the standard of care for a serious lung ... should not be used together to treat the disease, called ... rigorous independent study. The study, which will appear online ... to coincide with a presentation at the annual meeting ...
... Rosenfeld, M.D., M.P.H., of Seattle Children,s Hospital, and colleagues conducted ... rate of pulmonary exacerbations in children younger than 6 years ... recommended as therapy for patients 6 years or older with ... younger than 6 years. In the randomized trial, the ...
... obstructive sleep apnea (OSA) in children normalizes disturbances in ... according to a new study. "OSA is ... and executive function," said lead author Ann Halbower, MD, ... University of Colorado Denver. "Our study is the first ...
... Preliminary results from an ongoing, large-scale study by Yale ... naturally occurring substance produced in the brain and throughout ... known to process social information in children and adolescents ... Child Study Center research team that includes postdoctoral fellow ...
... News) -- Female athletes take longer to recover from ... have longer recovery times. The findings show that doctors ... into account when treating patients with concussions, said researchers ... from nearly 300 athletes in the United States who ...
... News) -- Older men have an increased risk of developing ... not know how to properly check themselves for signs of ... worrisome because nearly 132,000 new cases of melanoma will be ... which conducted the online poll. "This survey demonstrates that ...
Cached Medicine News:Health News:First, do no harm: Study finds danger in standard treatment for a serious lung disease 2Health News:First, do no harm: Study finds danger in standard treatment for a serious lung disease 3Health News:Treatment of childhood OSA reverses brain abnormalities 2Health News:Oxytocin improves brain function in children with autism 2Health News:Females, Young Athletes Take Longer to Get Over Concussions 2Health News:Melanoma a Big Threat to Older Men 2
... is a modular orthotic elbow system that can ... distal humeral fractures, proximal ulnar fractures or post ... K2 is a highly flexible system that provides ... assemble the brace that best fits your patients ...
The IROM Elbow is ideal for fixed or controlled ROM in the treatment of stable supracondylar fractures, stable radial fractures, and lateral/medial epicondylitis....
A lightweight soft good with rigid elbow protection. Designed by medical professionals with your needs in mind. Provides elbow stability for mild to moderate medial/lateral and hyperextension injurie...
Innovative support that immobilizes and positions elbow at 122 to minimize stretching of ulnar nerve...
Medicine Products: